It’s the last call for entries to the Cambridge Independent Science and Technology Awards 2025. With 15 categories available ...

The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed, Logos ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

Looking ahead, how do you see AstraZeneca’s advancements in ATTR-CM and the broader CVRM field shaping the future of patient care, especially as the company continues to focus on innovative ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens ... jointly developed with the Japanese company, was branded as Datroway and approved for patients ...

Understanding the enormous commercial potential of this market, the company continues to actively expand its portfolio of FDA-approved and experimental drugs. Overall, sales of AstraZeneca's ...

The institutional investor owned 10,908 shares of the company’s stock after selling 674 shares during the quarter. Mutual Advisors LLC’s holdings in AstraZeneca were worth $730,000 at the end ...